Repeated Dosing With Oral Cocaine in Humans: Assessment of Direct Effects, Withdrawal, and Pharmacokinetics

Sharon L. Walsh, William W. Stoops, David E. Moody, Shen Nan Lin, George Bigelow

Research output: Contribution to journalArticle

Abstract

Cocaine withdrawal symptoms are thought to play a role in relapse; studies characterizing the symptomatology have yielded mixed findings. This study sought to examine the pharmacodynamic/pharmacokinetic profile of repeated high dose exposure to oral cocaine and characterize acute and protracted withdrawal in cocaine abusers. This study employed a repeated-dosing, single-blind design in which subjects (n = 9), resided for 40 days on a closed ward. They were maintained for two 4-day cocaine exposure periods (Days 1-4 & Days 9-12, cocaine 175 mg, p.o.; 5 hourly doses; 875 mg/day) separated by a 4-day matched placebo exposure period (Days 5-8). After these 12 days, an additional period of 28 days of placebo maintenance followed (Days 13-40). Test sessions were conducted during each phase; measures of mood, drug effects, sleep, pharmacokinetics, and prolactin were collected throughout the study. The dosing regimen produced cocaine plasma concentrations (C max of 680 ng/mL) two to threefold higher than typically seen in acute dose studies. Prototypic psychostimulant effects, including subjective ratings of euphoric effects (liking, high, good effects) and significant cardiopressor effects, were sustained during the active dosing periods, corresponding to the rise and fall of plasma cocaine. Withdrawal-like symptoms (i.e., disruptions of sleep, increased ratings of anxiety, irritability, crashing) were observed within 24-hr after cessation of dosing. Cocaine reduced prolactin acutely, but no sustained alterations were observed for this measure or for other signs or symptoms during the 28-day abstinence period. These findings indicate that exposure to controlled high doses of cocaine produces modest symptoms consistent with cocaine withdrawal within hours of cessation of dosing but provide no evidence of symptoms persisting beyond 24 hours.

Original languageEnglish (US)
Pages (from-to)205-216
Number of pages12
JournalExperimental and Clinical Psychopharmacology
Volume17
Issue number4
DOIs
StatePublished - Aug 2009

Fingerprint

Cocaine
Pharmacokinetics
Substance Withdrawal Syndrome
Prolactin
Sleep
Placebos
Signs and Symptoms
Anxiety
Recurrence

Keywords

  • cocaine
  • pharmacokinetics
  • stimulants
  • withdrawal

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Psychiatry and Mental health

Cite this

Repeated Dosing With Oral Cocaine in Humans : Assessment of Direct Effects, Withdrawal, and Pharmacokinetics. / Walsh, Sharon L.; Stoops, William W.; Moody, David E.; Lin, Shen Nan; Bigelow, George.

In: Experimental and Clinical Psychopharmacology, Vol. 17, No. 4, 08.2009, p. 205-216.

Research output: Contribution to journalArticle

Walsh, Sharon L. ; Stoops, William W. ; Moody, David E. ; Lin, Shen Nan ; Bigelow, George. / Repeated Dosing With Oral Cocaine in Humans : Assessment of Direct Effects, Withdrawal, and Pharmacokinetics. In: Experimental and Clinical Psychopharmacology. 2009 ; Vol. 17, No. 4. pp. 205-216.
@article{46c300c43e6f407a974f5d2e3c53db0b,
title = "Repeated Dosing With Oral Cocaine in Humans: Assessment of Direct Effects, Withdrawal, and Pharmacokinetics",
abstract = "Cocaine withdrawal symptoms are thought to play a role in relapse; studies characterizing the symptomatology have yielded mixed findings. This study sought to examine the pharmacodynamic/pharmacokinetic profile of repeated high dose exposure to oral cocaine and characterize acute and protracted withdrawal in cocaine abusers. This study employed a repeated-dosing, single-blind design in which subjects (n = 9), resided for 40 days on a closed ward. They were maintained for two 4-day cocaine exposure periods (Days 1-4 & Days 9-12, cocaine 175 mg, p.o.; 5 hourly doses; 875 mg/day) separated by a 4-day matched placebo exposure period (Days 5-8). After these 12 days, an additional period of 28 days of placebo maintenance followed (Days 13-40). Test sessions were conducted during each phase; measures of mood, drug effects, sleep, pharmacokinetics, and prolactin were collected throughout the study. The dosing regimen produced cocaine plasma concentrations (C max of 680 ng/mL) two to threefold higher than typically seen in acute dose studies. Prototypic psychostimulant effects, including subjective ratings of euphoric effects (liking, high, good effects) and significant cardiopressor effects, were sustained during the active dosing periods, corresponding to the rise and fall of plasma cocaine. Withdrawal-like symptoms (i.e., disruptions of sleep, increased ratings of anxiety, irritability, crashing) were observed within 24-hr after cessation of dosing. Cocaine reduced prolactin acutely, but no sustained alterations were observed for this measure or for other signs or symptoms during the 28-day abstinence period. These findings indicate that exposure to controlled high doses of cocaine produces modest symptoms consistent with cocaine withdrawal within hours of cessation of dosing but provide no evidence of symptoms persisting beyond 24 hours.",
keywords = "cocaine, pharmacokinetics, stimulants, withdrawal",
author = "Walsh, {Sharon L.} and Stoops, {William W.} and Moody, {David E.} and Lin, {Shen Nan} and George Bigelow",
year = "2009",
month = "8",
doi = "10.1037/a0016469",
language = "English (US)",
volume = "17",
pages = "205--216",
journal = "Experimental and Clinical Psychopharmacology",
issn = "1064-1297",
publisher = "American Psychological Association Inc.",
number = "4",

}

TY - JOUR

T1 - Repeated Dosing With Oral Cocaine in Humans

T2 - Assessment of Direct Effects, Withdrawal, and Pharmacokinetics

AU - Walsh, Sharon L.

AU - Stoops, William W.

AU - Moody, David E.

AU - Lin, Shen Nan

AU - Bigelow, George

PY - 2009/8

Y1 - 2009/8

N2 - Cocaine withdrawal symptoms are thought to play a role in relapse; studies characterizing the symptomatology have yielded mixed findings. This study sought to examine the pharmacodynamic/pharmacokinetic profile of repeated high dose exposure to oral cocaine and characterize acute and protracted withdrawal in cocaine abusers. This study employed a repeated-dosing, single-blind design in which subjects (n = 9), resided for 40 days on a closed ward. They were maintained for two 4-day cocaine exposure periods (Days 1-4 & Days 9-12, cocaine 175 mg, p.o.; 5 hourly doses; 875 mg/day) separated by a 4-day matched placebo exposure period (Days 5-8). After these 12 days, an additional period of 28 days of placebo maintenance followed (Days 13-40). Test sessions were conducted during each phase; measures of mood, drug effects, sleep, pharmacokinetics, and prolactin were collected throughout the study. The dosing regimen produced cocaine plasma concentrations (C max of 680 ng/mL) two to threefold higher than typically seen in acute dose studies. Prototypic psychostimulant effects, including subjective ratings of euphoric effects (liking, high, good effects) and significant cardiopressor effects, were sustained during the active dosing periods, corresponding to the rise and fall of plasma cocaine. Withdrawal-like symptoms (i.e., disruptions of sleep, increased ratings of anxiety, irritability, crashing) were observed within 24-hr after cessation of dosing. Cocaine reduced prolactin acutely, but no sustained alterations were observed for this measure or for other signs or symptoms during the 28-day abstinence period. These findings indicate that exposure to controlled high doses of cocaine produces modest symptoms consistent with cocaine withdrawal within hours of cessation of dosing but provide no evidence of symptoms persisting beyond 24 hours.

AB - Cocaine withdrawal symptoms are thought to play a role in relapse; studies characterizing the symptomatology have yielded mixed findings. This study sought to examine the pharmacodynamic/pharmacokinetic profile of repeated high dose exposure to oral cocaine and characterize acute and protracted withdrawal in cocaine abusers. This study employed a repeated-dosing, single-blind design in which subjects (n = 9), resided for 40 days on a closed ward. They were maintained for two 4-day cocaine exposure periods (Days 1-4 & Days 9-12, cocaine 175 mg, p.o.; 5 hourly doses; 875 mg/day) separated by a 4-day matched placebo exposure period (Days 5-8). After these 12 days, an additional period of 28 days of placebo maintenance followed (Days 13-40). Test sessions were conducted during each phase; measures of mood, drug effects, sleep, pharmacokinetics, and prolactin were collected throughout the study. The dosing regimen produced cocaine plasma concentrations (C max of 680 ng/mL) two to threefold higher than typically seen in acute dose studies. Prototypic psychostimulant effects, including subjective ratings of euphoric effects (liking, high, good effects) and significant cardiopressor effects, were sustained during the active dosing periods, corresponding to the rise and fall of plasma cocaine. Withdrawal-like symptoms (i.e., disruptions of sleep, increased ratings of anxiety, irritability, crashing) were observed within 24-hr after cessation of dosing. Cocaine reduced prolactin acutely, but no sustained alterations were observed for this measure or for other signs or symptoms during the 28-day abstinence period. These findings indicate that exposure to controlled high doses of cocaine produces modest symptoms consistent with cocaine withdrawal within hours of cessation of dosing but provide no evidence of symptoms persisting beyond 24 hours.

KW - cocaine

KW - pharmacokinetics

KW - stimulants

KW - withdrawal

UR - http://www.scopus.com/inward/record.url?scp=69049090905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69049090905&partnerID=8YFLogxK

U2 - 10.1037/a0016469

DO - 10.1037/a0016469

M3 - Article

C2 - 19653786

AN - SCOPUS:69049090905

VL - 17

SP - 205

EP - 216

JO - Experimental and Clinical Psychopharmacology

JF - Experimental and Clinical Psychopharmacology

SN - 1064-1297

IS - 4

ER -